Allied Market Research

2024

Bipolar Disorder Therapeutics Market

Bipolar Disorder Therapeutics Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Class and by Mechanism of Action : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Bipolar disorder, also known as manic depression, is a mental disorder that could lead to periods of depression and elevated mood. The treatment of bipolar disorder includes psychotherapy as well as medications such as mood stabilizers and antipsychotics.

The global bipolar disorder therapeutics market is driven by increase in prevalence of bipolar disorder, government initiatives to increase public awareness about the effects of bipolar disorders, high demand for anti-depressants, and need to reduce the disease burden of bipolar disorder. However, dearth of proper diagnostic procedures for the identification of the disorder and the side effects associated with bipolar disorder therapeutics are expected to impede the market growth. On the contrary, advancements related to combination therapies of drugs provide lucrative opportunities for the market growth in the near future.

The global bipolar disorder market is segmented on the basis of drugs class, mechanism of action, and region. Based on drug class, it is classified into mood stabilizers, antipsychotics, antidepressant drugs, and other drugs. On the basis of mechanism of action, it is categorized into selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, and beta blockers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global market include AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Astellas Pharma Inc., Allergan plc., Johnson & Johnson., GlaxoSmithKline plc., AbbVie Inc., Pfizer Inc., and Novartis AG.

Key Benefits

  • The report presents the market analysis of the global bipolar disorder market along with the regional trend and future estimations.
  • It provides extensive information about the market segments to understand the market dynamics.
  • The key factors that drive, hamper, or provide opportunities to the market are provided in the report
  • Competitive landscape of the industry along with the profile analysis of market players is provided in the report.

Bipolar Disorder Therapeutics Market Report Highlights

Aspects Details
icon_5
By Drug Class
  • Mood Stabilizers
  • Antipsychotic Drugs
  • Antidepressant Drugs
  • Other Drugs
icon_6
By Mechanism of Action
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine Reuptake Inhibitors
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Benzodiazepines
  • Beta Blockers
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

Allergan plc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Astellas Pharma Inc.

Loading Table Of Content...

Bipolar Disorder Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2023-2032